2026-04-29T22:57:50Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/258892025-12-18T12:56:00Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587

00925njm 22002777a 4500 dc García-Pavía, Pablo author García-Pinilla, José Manuel author Lozano-Bahamonde, Ainara author Yun, Sergi author García-Quintana, Antonio author Gavira-Gómez, Juan José author Aibar-Arregui, Miguel Ángel author Barge-Caballero, Gonzalo author Núñez Villota, Julio author Bernal, Laura author Tarilonte, Patricia author 2024-07-31 Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence of ATTR-CA among HFpEF patients in a multicenter nationwide study. Consecutive ambulatory or hospitalized patients aged ≥ 50 years with HFpEF and left ventricle hypertrophy ≥ 12mm were studied at 20 Spanish hospitals. Screening for cardiac amyloidosis was initiated according to the usual clinical practice of each center. Positive scintigraphs were centrally analyzed. 422 patients were included, of whom 387 underwent further screening for cardiac amyloidosis. A total of 65 patients (16.8%) were diagnosed with ATTR-CA, none below 75 years. There was an increase of prevalence with age. Of them, 60% were male, with a mean age of 85.3±5.2 years, mean left ventricle ejection fraction of 60.3±7.6% and a mean maximum left ventricle wall thickness of 17.2 [12-25] mm. Most of the patients were New York Heart Association class II (48.4%) or III (46.8%). Besides being older than non-ATTR-CA patients, ATTR-CA patients had higher median NT-proBNP levels (3801 [2266-7132] vs 2391 [1141-4796] pg/mL; P=.003). There was no statistical difference in the prevalence of ATTR-CA by sex (19.7% for men and 13.8% for women, P=.085). A ∼7% (4/56) of the patients exhibited a genetic variant (ATTRv). This multicenter nationwide study found a prevalence of 16.8%, confirming that ATTR-CA is a significant contributor to HFpEF in male and female patients with left ventricle hypertrophy and more than 75 years. Rev Esp Cardiol. 2024 Jul 31:S1885-5857(24)00240-8. Revista Española de Cardiología 39089574 https://hdl.handle.net/20.500.12105/25889 Amiloidosis cardiaca Amiloidosis cardiaca por transtirretina Cardiac amyloidosis Fracción de eyección conservada Heart failure Hipertrofia del ventrículo izquierdo Insuficiencia cardiaca Left ventricular hypertrophy Preserved ejection fraction Prevalence Prevalencia Transthyretin Transthyretin cardiac amyloidosis Transtirretina Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.